Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226154 · ClinicalTrials.gov registry record
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
A clinical trial of Pancreatic Ductal Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT07226154 is a study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 200 participants, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07226154, a study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Small RNA sequencing
- DIAGNOSTIC_TEST PRECEPT assay (qRT-PCR validation)
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226154
The ClinicalTrials.gov registry entry for NCT07226154 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (67% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Small RNA sequencing is the first listed.
NCT07226154 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07226154 about?
NCT07226154 is a clinical study titled "Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer". This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT07226154?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-11-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07226154 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT07226154?
The interventions under investigation include: Small RNA sequencing (DIAGNOSTIC_TEST), PRECEPT assay (qRT-PCR validation) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07226154?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226154 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.